NASDAQ
03.06.26 | 21:59
4,760 US-Dollar
+0,21 % +0,010
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Shattuck Labs, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.05. | Shattuck Labs GAAP EPS of -$0.13 in-line | 2 | Seeking Alpha | ||
| 07.05. | Shattuck Labs, Inc.: Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights | 300 | GlobeNewswire (Europe) | Phase 1 clinical trial of SL-325 enrollment complete; data expected in the second quarter of 2026 -Phase 2 clinical trial of SL-325 in patients with Crohn's disease expected to initiate in the third... ► Artikel lesen | |
| SHATTUCK LABS Aktie jetzt für 0€ handeln | |||||
| 07.05. | Shattuck Labs, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.05. | Shattuck Labs, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.03. | Why Shattuck Labs Stock Soared More Than 53% Higher This Week | 2 | The Motley Fool | ||
| 06.03. | Shattuck Labs stock maintained at Buy by TD Cowen on drug data | 1 | Investing.com | ||
| 05.03. | Insights into Shattuck Labs Q4 Earnings | 1 | Benzinga.com | ||
| 05.03. | Shattuck Labs, Inc Q4 Loss Drops | 2 | RTTNews | ||
| 05.03. | Shattuck Labs, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 05.03. | Shattuck Labs GAAP EPS of -$0.12 beats by $0.01 | 1 | Seeking Alpha | ||
| 05.03. | Shattuck Labs, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.03. | Shattuck Labs, Inc.: Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights | 481 | GlobeNewswire (Europe) | Phase 1 clinical trial of SL-325 ongoing, with data expected in the second quarter of 2026 -Phase 2 clinical trial of SL-325 in patients with Crohn's disease expected to initiate in the third quarter... ► Artikel lesen | |
| 05.02. | Shattuck Labs, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 28.01. | Piper Sandler stuft Shattuck Labs mit "Overweight" ein und sieht massives Aufwärtspotenzial | 4 | Investing.com Deutsch | ||
| 28.01. | Piper Sandler initiates Shattuck Labs stock with Overweight rating | 1 | Investing.com | ||
| 22.01. | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.01. | Why Shattuck Labs Stock Soared in December | 1 | The Motley Fool | ||
| 15.12.25 | Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 06.11.25 | Shattuck Labs, Inc.: Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights | 291 | GlobeNewswire (Europe) | -First participants dosed in Phase 1 clinical trial of SL-325 in healthy volunteers - - Closed a private placement of up to $103 million in August 2025 to support advancement of SL-325 - - Appointments... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NUREXONE BIOLOGIC | 0,377 | +3,01 % | NurExone Biologic EU-Programm rückt Exosomen-Therapien stärker ins Rampenlicht | ||
| ONCO-INNOVATIONS | 0,619 | +3,00 % | Onco-Innovations Limited: Onco-Innovations Advances 1kg Scale-Up of B4 Precursor Supporting ONC010 Manufacturing and Clinical Development Program | Also Announces Marketing Program VANCOUVER, BC / ACCESS Newswire / June 2, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H) (WKN: A3EKSZ) ("Onco" or the "Company") announces... ► Artikel lesen | |
| FRACTYL HEALTH | 0,760 | -0,01 % | Fractyl Health names Mike Zumdahl as market access head | ||
| MINERALYS THERAPEUTICS | 25,050 | -0,04 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 278,89 | -0,01 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen | |
| QIAGEN | 30,975 | +0,88 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Interesse der Investoren habe vor allem dem Tuberkulosetest... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,470 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | ||
| TANGO THERAPEUTICS | 21,470 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points... ► Artikel lesen | |
| ERASCA | 13,170 | -0,08 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| COGENT BIOSCIENCES | 32,220 | -0,12 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) ... | Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 36,030 | 0,00 % | Enliven to host webcast on ELVN-001 trial data June 11 | ||
| IMMUNOVANT | 31,110 | -0,13 % | H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data | ||
| SUMMIT THERAPEUTICS | 15,075 | +0,03 % | Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock | ||
| APOGEE THERAPEUTICS | 84,19 | 0,00 % | Weekly Buzz: AstraZeneca, JNJ Get FDA Nod; Eli Lilly To Acquire Curevo; APGE Advances Zumilokibart | NEW BRUNSWICK (dpa-AFX) - This week in the biotech space, there were regulatory approvals across the U.S. and Europe, collaborations, acquisitions, and positive data readouts spanning multiple... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 37,500 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel | SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen |
SHATTUCK LABS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 4,760 Euro und damit +0,21 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHATTUCK LABS INC finden Sie auf Wallstreet Online.